A groundbreaking new study suggests it may be possible to protect babies from HIV with a single injection given at birth—a one-time gene‑therapy treatment that, in monkeys, kept HIV at bay for at least three years. This could transform prevention in high-risk regions where paediatric HIV transmission remains high.
The study, published in Nature and conducted by researchers from Tulane University and the California National Primate Research Center, involved administering a harmless adeno‑associated virus (AAV) carrying genetic instructions to produce broadly neutralising antibodies (bNAbs) against HIV. The therapy was delivered to newborn rhesus macaques within their first month of life. As reported by Tulane University, infants treated within 48 hours of birth maintained antibody levels capable of preventing infection for up to four years, without the need for booster doses. In contrast, monkeys treated at 8–12 weeks failed to mount the same durable response, as their immune systems had already matured and rejected the therapy.
Why timing matters, and why this could make a difference
During the earliest weeks of life, the neonatal immune system is naturally more tolerant, as there’s a built‑in window that allows foreign substances like the therapy’s viral vectors to be accepted rather than attacked. As immunologist Amir Ardeshir, lead author of the study, explained, “This is a one‑and‑done treatment that fits the critical time when these mothers with HIV in resource‑limited areas are most likely to see a doctor.” The macaques treated early responded robustly, expressing high levels of bNAbs that neutralised multiple HIV strains. Those treated later often developed anti‑drug antibodies that shut down effectiveness.
More than 100,000 children acquire HIV each year, mostly via mother‑to‑child transmission during childbirth or breastfeeding. Conventional antiretroviral therapy (ART) works by suppressing the virus if taken diligently, but efforts collapse when access falters after birth, particularly in sub‑Saharan Africa. This therapy sidesteps that challenge: one injection delivered at birth, and the baby’s own muscle cells act as mini‑factories continuously manufacturing HIV‑neutralising antibodies.
As highlighted by GEN News, the vector targets long-lived muscle cells, meaning the therapeutic effect endures over time. The bNAb chosen, 3BNC117, is known to neutralise a wide range of HIV strains. Although the macaque study used only one SHIV strain, the therapy’s broad activity suggests potential effectiveness across different HIV types.
What this could mean for the future of infectious disease protection
This gene-therapy platform isn’t just limited to HIV. The same approach of using a viral vector to teach the body to produce protective antibodies could potentially be adapted for other infectious diseases. In regions where malaria, respiratory syncytial virus (RSV), or even tuberculosis cause major childhood mortality, a single-shot intervention could change the public health landscape. Studies exploring these possibilities are already in early stages, with promising signs that similar strategies could be viable.
The therapy also removes the logistical hurdles tied to cold storage and daily adherence. The AAV vector is stable at room temperature, making it a practical option for healthcare systems in low-income countries. And because it’s administered once, it avoids the issues seen with long-term ART adherence, which often breaks down in resource-constrained environments.
There are still challenges to overcome—namely, translating this success in monkeys to human infants. Safety trials will need to proceed cautiously, especially considering the immune system’s variability in human newborns. There’s also the question of cost: AAV-based therapies remain expensive to manufacture, but ongoing innovation is bringing those costs down.
If this technology proves successful in people, it could reshape how the world thinks about paediatric infectious disease prevention. For HIV alone, it offers a potential solution in places where mother-to-child transmission has remained stubbornly difficult to eliminate, despite decades of effort. And beyond HIV, it opens the door to a new way of protecting the most vulnerable children around the world with a single jab in their earliest days of life.